With a majority of cell immunotherapies in development today use CAR T cells, the number of therapeutic options will only increase. One forecast predicts that the CAR T-cell market will grow to $6.1 billion by 2030. But despite the promise of CAR T cells, developers must work out the kinks in their manufacture.
In this paper, we discuss why CAR T-cell therapy is so exciting, note some common hurdles in development and manufacturing, and propose Droplet Digital PCR as a solution for some of these issues.
Offered Free by: Bio-Rad
See All Resources from: Bio-Rad
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.